EA201990513A1 - АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ - Google Patents

АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ

Info

Publication number
EA201990513A1
EA201990513A1 EA201990513A EA201990513A EA201990513A1 EA 201990513 A1 EA201990513 A1 EA 201990513A1 EA 201990513 A EA201990513 A EA 201990513A EA 201990513 A EA201990513 A EA 201990513A EA 201990513 A1 EA201990513 A1 EA 201990513A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
bone diseases
pparγ agonist
pparγ
agonist
Prior art date
Application number
EA201990513A
Other languages
English (en)
Russian (ru)
Inventor
Деннис Ланфир
Original Assignee
Интекрин Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интекрин Терапьютикс, Инк. filed Critical Интекрин Терапьютикс, Инк.
Publication of EA201990513A1 publication Critical patent/EA201990513A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
EA201990513A 2016-08-18 2017-08-18 АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ EA201990513A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662376732P 2016-08-18 2016-08-18
PCT/US2017/047584 WO2018035449A1 (en) 2016-08-18 2017-08-18 Pparϒ agonist for treatment of bone disorders

Publications (1)

Publication Number Publication Date
EA201990513A1 true EA201990513A1 (ru) 2019-08-30

Family

ID=61197122

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990513A EA201990513A1 (ru) 2016-08-18 2017-08-18 АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ

Country Status (11)

Country Link
US (1) US20190167660A1 (enExample)
EP (1) EP3500269A4 (enExample)
JP (2) JP2019524889A (enExample)
KR (1) KR20190065252A (enExample)
CN (1) CN109843292A (enExample)
AU (1) AU2017313842A1 (enExample)
BR (1) BR112019003133A2 (enExample)
CA (1) CA3033971A1 (enExample)
EA (1) EA201990513A1 (enExample)
SG (2) SG10202101500WA (enExample)
WO (1) WO2018035449A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
JP2024013883A (ja) * 2022-07-21 2024-02-01 株式会社三洋物産 遊技機
JP2024013885A (ja) * 2022-07-21 2024-02-01 株式会社三洋物産 遊技機
JP2024013886A (ja) * 2022-07-21 2024-02-01 株式会社三洋物産 遊技機

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
CA2555914A1 (en) * 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
HK1218510A1 (zh) * 2013-01-30 2017-02-24 Intekrin Therapeutics, Inc. 用於治療多發性硬化症的PPARγ激動劑
PL3203999T3 (pl) * 2014-10-10 2020-07-27 Liminal Biosciences Limited Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy

Also Published As

Publication number Publication date
AU2017313842A1 (en) 2019-03-07
US20190167660A1 (en) 2019-06-06
CN109843292A (zh) 2019-06-04
SG11201901328VA (en) 2019-03-28
EP3500269A1 (en) 2019-06-26
JP2019524889A (ja) 2019-09-05
EP3500269A4 (en) 2020-04-15
CA3033971A1 (en) 2018-02-22
JP2022116294A (ja) 2022-08-09
WO2018035449A1 (en) 2018-02-22
KR20190065252A (ko) 2019-06-11
BR112019003133A2 (pt) 2019-05-21
SG10202101500WA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
CU20210029A7 (es) Inhibidores de proteína tirosina fosfatasa shp2 útiles en el tratamiento de enfermedades
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
MX373154B (es) Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
MX380092B (es) Tratamiento de la osteoartritis.
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
EA201691135A1 (ru) Новые ингибиторы глутаминазы
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
MY195437A (en) Methods of Treatment for Cholestatic and Fibrotic Diseases
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201591382A1 (ru) Ингибиторы гистондеметилаз
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
EA201791095A1 (ru) Способ лечения рака
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX391040B (es) Formulacion de alta concentracion.
EA201890567A1 (ru) Способ лечения рака
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
BR112017006420A2 (pt) derivados de ácido borônico
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций